PHARMACY BENEFIT MANAGERS (PBMS) -- UNACCOUNTABLE DRUG INDUSTRY MIDDLEMEN

Pharmacy Benefit Managers (PBMs) serve as administrators of prescription drug plans (PDPs). PBMs are responsible for developing and maintaining clinically appropriate drug formularies, negotiating contracts with pharmaceutical manufacturers, wholesalers and pharmacies -- often represented through group negotiating entities like pharmacy services administrative organizations (PSAOs).

PBMs process prescription drug claims for PDPs, including Medicare and Medicaid plans, employer-sponsored plans, and plans in the individual market. PBMs typically generate income from drug manufacturers through two primary payment mechanisms -- generally known as “rebates:” formulary payments to earn preferred formulary standing, and market-share payments designed to foster utilization of their pharmaceutical products relative to their competition.

PBMs also extract various administrative fees and charges from pharmacies, which generally are buried in lengthy contractual language. In some cases, these contracts actually prevent the pharmacy or pharmacist from informing consumers that it would be less expensive to pay for a prescription entirely out-of-pocket instead of going through the PBM and paying a co-pay or deductible.

In most long term care pharmacy (LTCP) agreements, pharmacies must pay a fee per prescription, usually ranging from $.025/claim to $1.25/claim. LTCPs appear to be the only providers of any type ultimately paid by Medicare or Medicaid, which must pay a fee to third party intermediaries -- simply to get paid. This is but one example of rapacious post point-of-sale fees and clawbacks PBMs impose on LTCPs.

With greater demand from consumers, Congress, regulators and the media about the need for more competition and pricing transparency in our increasingly complex and tumultuous pharmaceutical marketplace, PBMs -- long content to remain out of the public eye -- are increasingly viewed as unaccountable, opaque middlemen. Due to substantial marketplace consolidation, three PBMs now process over 80% of prescriptions dispensed by the nation’s roughly 1,300 LTCPs. Still worse, each of the three major PBMs is owned by, or has a shared parent, with an insurer, large retail, specialty or LTC pharmacy chain, or mail-order pharmacy. Such arrangements are rife with possible conflicts of interest in what has become an oligopolistic market.

Maximum Allowable Cost (MAC) Pricing
Under Medicare Part D, PBMs use so-called Maximum Allowable Cost (MAC) pricing to set reimbursement rates for most generic drugs LTCPs dispense to Medicare beneficiaries. Nearly 90% of all medications dispensed by LTC pharmacies to seniors are generics. MAC prices may vary during the year, but any changes in price must be justified by changes in market conditions.

Avalere Health LTC Pharmacy/PBM Pricing Data Spotlights Anti-Competitive PBM Pricing Policies
An Avalere Health pricing data analysis between PBMs and LTC pharmacies finds increasing reimbursement inequities driven by nontransparent MAC pricing methodologies. The data clearly show MAC prices paid for the same generic drugs, on the same day, by different payers, can vary considerably. SCPC maintains this raises questions about PBMs’ claim that market conditions determine reimbursement rates.
In effect, MAC pricing is not really market pricing at all – and is inconsistent with the free market principles underlying the Part D program. Due to PBMs’ veiled pricing practices, it remains a mystery to consumers and pharmacies alike how PBMs determine prices and covered pharmaceutical product lists under this MAC pricing formula – despite a recent regulatory change designed to make these pricing practices more transparent.

**January 2017 -- CMS Finds PBMs Keeping “Rebates” at Expense of Consumers, Taxpayers**

A January 2017 Centers for Medicare & Medicaid Services (CMS) report finds that drug companies and pharmacies are paying larger rebates to PBMs and insurers, but that these **PBM**s are keeping the money rather than translating it into lower costs for government health care programs or **beneficiaries**. CMS data show that since 2010, the growth in rebates or concessions paid by drug companies or pharmacies to PBMs or managed care plans (in addition to the lump sum payment plans received from Medicare) after the point of sale (called Direct and Indirect Remuneration or DIR) has far outpaced the growth in Part D drug costs. The DIR that plans report to CMS increased from $31 billion in 2012 to $50 billion in 2015.

**Bicameral Improving Transparency and Accuracy in Medicare Part D Drug Spending Act Introduced**

S. 413, introduced by Sens. Shelley Moore Capito (R-WV) and Jon Tester (D-MT), and House companion bill, H.R. 1038, introduced by Reps. Morgan Griffith (R-VA) and Peter Welch (D-VT), will curtail the ability of PBMs from extracting retroactive direct and indirect remuneration (DIR) fees in transactions with patients, long term care (LTC) pharmacies and the Medicare program. Passage of the bills into law will begin to address DIR fee abuses, and other unfair practices such as “switching fees”, that negatively affect patients, LTCPs and the Medicare program itself. Sen. Chuck Grassley (R-IA), significantly, is also a co-sponsor on the Senate measure.

**Prescription Drug Price Transparency Act Introduced in House**

U.S. Reps. Doug Collins (R-GA) and Dave Loebsack (D-IA) have introduced H.R. 1316, the Prescription Drug Price Transparency Act, which would be a strong first step towards more equitable, transparent reimbursement for LTC pharmacies dispensing generic drugs to seniors. Opaque PBM pricing practices make it impossible for LTC pharmacies to predict how they will be reimbursed for the generic drugs they dispense under Medicare Part D.

**Creating Transparency to Have Drug Rebates Unlocked Act (C-THRU) Introduced in Senate**

S.637, introduced by Senate Finance Committee Ranking Member Ron Wyden (D-OR), requires PBMs to publicly disclose data regarding “rebates,” “discounts” and other accrued payments — and their impact on Medicare Part D beneficiaries and the Part D program overall. The SCPC supports this legislation as a step toward pulling back the curtain on duplicitous PBM “rebates,” suspect pricing schemes, and related anti-competitive behavior.

PBM MAC pricing and administrative abuses undermine the ability of LTCPs to appropriately serve the patients under their care, and these practices also increase out-of-pocket expenses for consumers and add unnecessarily to Medicare’s prescription drug expenditures -- not only under Part D, but also under Part B. The time has come for a thorough, searching investigation into PBM pricing and other predatory practices, particularly as they impact LTCPs and their patients. SCPC seeks to work with lawmakers on a constructive, bipartisan basis to bring about more transparency and restrict anti-competitive behavior by the de facto oligopolies that have come to dominate the LTC pharmacy sector, as well as the entire pharmaceutical marketplace.